Hradec J, Král J, Janota T, Marek J
III. interní klinika, 1. lékarské fakulty, Univerzity Karlovy, Prague, Crech Republic.
Sb Lek. 1995;96(4):433-5.
Evidence has accumulated regarding acromegalic heart muscle disease which existence now appears to be unequivocal. We took an advantage of a large group of acromegalic patients being followed-up at our institution for a long time and have studied pattern, nature and reversibility of acromegalic heart disease. Its major manifestation is cardiac hypertrophy expressed especially as left ventricular hypertrophy. The cardiac hypertrophy is slowly reversible after normalization of plasma growth hormone levels due to successful treatment. This we have first suggested on the basis of a retrospective analysis of clinical and echocardiographic data in 78 patients with acromegaly and subsequently confirmed by a 10-year prospective follow-up of the original patient cohort. We have also showed that effective treatment of acromegaly with a new slow release somatostatine analogue lanreotide leads to regression of cardiac hypertrophy.
关于肢端肥大症性心肌病的证据不断积累，现在其存在似乎已明确无疑。我们利用了一大群在我们机构长期随访的肢端肥大症患者，研究了肢端肥大症性心脏病的模式、性质和可逆性。其主要表现为心脏肥大，尤其是左心室肥大。由于治疗成功，血浆生长激素水平正常化后，心脏肥大可缓慢逆转。这是我们首先基于对78例肢端肥大症患者的临床和超声心动图数据进行回顾性分析提出的，随后通过对原始患者队列进行10年的前瞻性随访得到证实。我们还表明，用新的缓释生长抑素类似物兰瑞肽有效治疗肢端肥大症可导致心脏肥大消退。
